AVN 49.56 Decreased By ▼ -1.29 (-2.54%)
BAFL 28.70 Decreased By ▼ -0.16 (-0.55%)
BOP 3.68 Decreased By ▼ -0.02 (-0.54%)
CNERGY 3.30 Decreased By ▼ -0.01 (-0.3%)
DFML 11.14 Increased By ▲ 0.14 (1.27%)
DGKC 52.75 Decreased By ▼ -0.37 (-0.7%)
EPCL 44.20 Increased By ▲ 0.19 (0.43%)
FCCL 12.75 Increased By ▲ 0.15 (1.19%)
FFL 6.29 Increased By ▲ 0.02 (0.32%)
FLYNG 5.99 Decreased By ▼ -0.09 (-1.48%)
GGL 10.50 Decreased By ▼ -0.20 (-1.87%)
HUBC 68.70 No Change ▼ 0.00 (0%)
HUMNL 5.87 Decreased By ▼ -0.13 (-2.17%)
KAPCO 22.66 Decreased By ▼ -0.24 (-1.05%)
KEL 1.85 Decreased By ▼ -0.01 (-0.54%)
LOTCHEM 29.30 Decreased By ▼ -0.22 (-0.75%)
MLCF 28.85 Decreased By ▼ -0.10 (-0.35%)
NETSOL 77.70 Decreased By ▼ -2.63 (-3.27%)
OGDC 79.19 Increased By ▲ 0.29 (0.37%)
PAEL 9.85 Decreased By ▼ -0.05 (-0.51%)
PIBTL 4.26 Decreased By ▼ -0.07 (-1.62%)
PPL 61.39 Increased By ▲ 0.11 (0.18%)
PRL 14.69 Decreased By ▼ -0.05 (-0.34%)
SILK 1.06 Decreased By ▼ -0.01 (-0.93%)
SNGP 42.40 Decreased By ▼ -0.30 (-0.7%)
TELE 7.15 Decreased By ▼ -0.17 (-2.32%)
TPLP 13.10 Increased By ▲ 0.13 (1%)
TRG 97.85 Decreased By ▼ -2.58 (-2.57%)
UNITY 15.22 Increased By ▲ 0.72 (4.97%)
WTL 1.19 Decreased By ▼ -0.02 (-1.65%)
BR100 4,195 Decreased By -16.6 (-0.4%)
BR30 14,555 Decreased By -49.7 (-0.34%)
KSE100 41,987 Decreased By -155.9 (-0.37%)
KSE30 14,852 Decreased By -90.9 (-0.61%)
Follow us

SINGAPORE: Pfizer has been ranked first in its Covid-19 response, patient centricity, patient safety and bringing innovative, high-quality products amongst pharma companies in Asia in the ‘Corporate Reputation of Pharma’ survey by patient groups across the APAC region. Overall, the company is ranked second for its corporate reputation across Asian countries.

Pfizer moved up in the survey rankings from 4th place to occupy the top ranking in terms of patient groups ‘working’ with Pfizer, representing a significant increase in rankings in 2021 vs. 2020, in 10 Asian countries.

This survey, conducted by UK-based PatientView, measures various aspects of pharma’s performance at corporate reputation—always from a patient perspective. Patient groups responding to this survey are working across therapeutic areas and uniquely positioned to comment on the pharma industry’s performance during the pandemic.

Copyright Business Recorder, 2022

Comments

1000 characters

Pfizer ranked as leading company in Asia for Covid-19 response

Intra-day update: rupee largely stable against US dollar

Rs90bn allocated for parliamentarians under SDGs

Oil eases as weaker demand outlook returns to focus

PSDP: Govt takes firm step to revive certain CPEC initiatives

IT exporters, freelancers: 35pc of export proceeds can be retained in special forex accounts: SBP

IK and Qureshi meet, exchange wincing smiles

Finally, JKT launches new party to cash in on IK’s misery

Survey contains details of major socioeconomic indicators: MoF

NEC apprised about the key challenges facing economy

Sustainable Development Achievement Goals Programme: ECC approves Rs27bn supplementary grants